CVS Health Corporation (CVSH34) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CVS Health Corporation BRL 19.72, price BRL 45.24, upside -56.4%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CVS Health Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range R$25.71 – R$55.22 · fair‑value band R$11.86 – R$19.76 · the R$45.24 price screens above the R$19.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Follow CVS Health in your weekly email
Every Wednesday you see whether CVS Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.
Show more
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Stock analysis
CVS Health Corporation (CVSH34) currently trades at R$45.24, while our model-based Fair Value estimate is R$19.72, 56.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$25.96 per share, and 4 of the 24 models we run sit above the R$45.24 price.
Bear case: the Earnings-Based group reads lowest at R$6.31, and 20 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: R$11.86 (bear) to R$19.76 (bull), the price of R$45.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CVS Health Corporation reported revenue of $402B in FY2025 versus $292B in FY2021, a compound +8.3%/yr. Reported net income was $1.8B in FY2025, compounding −31.2%/yr from FY2021.
Key figures
Market cap R$690B (≈ $132B) · P/E ratio 38.3 · P/S ratio 0.17 · EPS (TTM) R$1.18 · Dividend yield 5.9% · Net margin 0.4% · Return on equity 3.8% · Return on assets (EBIT) 4.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at −56%, CVSH34 screens richer than that median.
Fair Value models
Bear R$11.86Fair Value R$19.72Bull R$19.76
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.0%
Dividend (yield on the price)5.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 1%
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Plans” was too small, so the broader sector is used.)Health Care · 2315 stocks
Beats the sector median on 5/11 measures
A mixed picture versus its sector peers.
Valuation
Quality Score58 · Above median
Fair Value upside−50.2% · Below median
Profitability
Return on equity (TTM)3.8% · Below median
Return on assets2.7% · Above median
Net margin (TTM)0.7% · Below median
Operating margin (TTM)4.1% · Below median
Growth and dividend
Revenue growth6.1% · Above median
Dividend yield (TTM)5.9% · Top 25%
Balance sheet
Debt / equity0.79× · Highest 25%
Valuation Multiplesvs Health Care median · lower = cheaper
P/E (TTM)38.3× · Pricier than median
PEG0.29× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)31· sector 26
PAST (return on equity)15· sector 16
HEALTH (low debt)61· sector 96
DIVIDEND (yield)100· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CVS Health Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CVSH34
Frequently asked questions
Is CVS Health Corporation (CVSH34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$19.72 versus a price of R$45.24, about −56% upside (overvalued).
What is the fair value of CVSH34?
Our model-based fair value for CVS Health Corporation is R$19.72 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$45.24.
What is the quality score of CVSH34?
CVS Health Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CVS Health Corporation (CVSH34)?
Our model-based price target is the fair value of R$19.72 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario R$11.86, optimistic scenario R$19.76. It is a calculation from audited fundamentals, not an analyst target.
What is the CVS Health Corporation stock forecast for 2026?
Our models put fair value at R$19.72, about −56% upside versus a price of R$45.24 (overvalued). Cautious scenario R$11.86, optimistic scenario R$19.76. The calculation is refreshed regularly with new filings.
What is the revenue of CVS Health Corporation (CVSH34)?
CVS Health Corporation reported trailing-twelve-month revenue of about $406B (latest available figure, as of Sep 29, 2026).
Does CVS Health Corporation pay a dividend?
CVS Health Corporation currently shows a dividend yield of about 5.88% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of CVS Health Corporation (CVSH34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CVS Health Corporation it is R$19.72 per share (as of Sep 29, 2026), against a price of R$45.24. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is CVS Health Corporation stock overvalued or undervalued in 2026?
As of Sep 29, 2026, CVSH34 trades above its calculated fair value: price R$45.24, fair value R$19.72, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVSH34?
No. The price is what the market pays today (R$45.24); the fair value is what the company's own numbers justify (R$19.72). For CVS Health Corporation the two are R$25.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is CVS Health Corporation worth?
The market values CVS Health Corporation at about R$690B (market capitalisation, as of Sep 29, 2026). Per share that is R$45.24; our models calculate a fair value of R$19.72 per share.
What do the bullish and bearish scenarios say about CVSH34?
Our models span a range for CVS Health Corporation: cautious scenario R$11.86, base R$19.72, optimistic R$19.76 per share (as of Sep 29, 2026, price R$45.24). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CVSH34?
CVS Health Corporation trades at a price-to-earnings ratio of 38.3 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$19.72 is built from several models across several years. Other multiples: PEG 0.3.
What is the PEG ratio of CVSH34?
The PEG ratio of CVS Health Corporation is 0.29 (P/E divided by earnings growth, as of Sep 29, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of CVS Health Corporation (CVSH34)?
Balance-sheet figures for CVS Health Corporation (as of Sep 29, 2026): return on equity 3.8%, debt of 0.79 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is CVSH34 from its 52-week high?
CVS Health Corporation trades at R$45.24, about 18% below its 52-week high of R$55.22 and 24% above the low of R$36.41 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$19.72 is for.
Which stocks are comparable to CVS Health Corporation?
From the same area (Healthcare) we also value UnitedHealth Group, Elevance Health, Inc, The Cigna Group, Humana Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CVS Health Corporation stock attractive at the current price?
The data as of Sep 29, 2026: price R$45.24, calculated fair value R$19.72 (−56%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVSH34 calculated?
We run CVS Health Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$19.72, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. CVS Health Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CVS Health Corporation (CVSH34)?
The closing price on Oct 2, 2026 was R$45.24. Our model-based fair value is R$19.72, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CVS Health Corporation right now?
The price sits above even our optimistic bull case (R$19.76). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of CVS Health Corporation
How large is the market capitalisation of CVS Health Corporation (CVSH34)?
The market capitalisation of CVS Health Corporation is R$690B (≈ $132B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CVS Health Corporation (CVSH34)?
The price-to-sales ratio of CVS Health Corporation is 0.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CVS Health Corporation (CVSH34)?
Earnings per share at CVS Health Corporation are R$1.18 (price ÷ EPS = P/E 38.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CVS Health Corporation (CVSH34)?
The dividend yield of CVS Health Corporation is 5.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CVS Health Corporation (CVSH34)?
The net margin of CVS Health Corporation is 0.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CVS Health Corporation (CVSH34)?
The return on equity (ROE) of CVS Health Corporation is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CVS Health Corporation (CVSH34)?
On an EBIT basis the return on assets of CVS Health Corporation is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CVS Health Corporation (CVSH34)?
The operating margin of CVS Health Corporation is 4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CVS Health Corporation (CVSH34)?
Revenue at CVS Health Corporation is growing +6.1% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CVS Health Corporation (CVSH34)?
Earnings per share at CVS Health Corporation are growing +63.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CVS Health Corporation (CVSH34) generate?
The free cash flow of CVS Health Corporation is $7.8B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CVS Health Corporation (CVSH34) carry?
The net debt of CVS Health Corporation is $56.1B (fiscal year 2025, ≈ 7.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CVS Health Corporation in the live analysis
One click puts CVS Health Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
